Facio presents its business approach at the Dutch Life Sciences Conference

November 17, 2016

Facio Therapies will present its business approach at the Dutch Life Sciences Conference in Leiden, the Netherlands, on November 24th, 2016.

Facio’s single goal is to develop a causal therapy for facioscapulohumeral dystrophy (FSHD), a devastating muscle wasting disease that affects over 700,000 people worldwide. With active support from the global FSHD community, Facio is committed to maximizing the accessibility and affordability of its therapeutics. This calls for a socially responsible business model that will allow the creation of sustainable value for people with FSHD and shareholders alike.

Facio’s Chairman, Kees van der Graaf, will present Facio’s business approach during the Dutch Life Sciences Conference at the ‘ECC Leiden’ in Leiden, the Netherlands, on November 24th , 2016, at 13:30 - 15:00 (CET). Kees, a former member of the executive board of Unilever, co-founded Facio in 2014. Together with his wife, Renée, he also founded the Dutch FSHD Foundation (the FSHD Stichting), which he still chairs.